Management of Bipolar Disorder in the Intercontinental Region: An International, Multicenter, Non-Interventional, Cross-Sectional Study in Real-Life Conditions Publisher Pubmed



Samalin L^{1, 2} ; Vieta E² ; Okasha TA³ ; Uddin MMJ⁴ ; Ahmadi Abhari SA⁵ ; Nacef F⁶ ; Mishyiev V⁷ ; Aizenberg D⁸ ; Ratner Y⁹ ; Melasmelt L¹⁰ ; Sedeki I¹¹ ; Llorca PM¹ Show Affiliations
Source: Scientific Reports Published:2016

Abstract

Most of the existing data on real-life management of bipolar disorder are from studies conducted in western countries (mostly United States and Europe). This multinational, observational cohort study aimed to describe the management and clinical outcomes of bipolar patients in real-life conditions across various intercontinental countries (Bangladesh, Egypt, Iran, Israel, Tunisia, and Ukraine). Data on socio-demographic and disease characteristics, current symptomatology, and pharmacological treatment were collected. Comparisons between groups were performed using standard statistical tests. Overall, 1180 patients were included. The median time from initial diagnosis was 80 months. Major depressive disorder was the most common initial diagnosis. Mood stabilizers and antipsychotics were the most common drugs being prescribed at the time of the study. Antidepressants (mainly selective serotonin uptake inhibitors [SSRIs]) were administered to 36.1% of patients. Patients with bipolar I disorder received higher number of antipsychotics and anxiolytics than those with bipolar II disorder (p < 0.001). Presence of depressive symptoms was associated with an increase in antidepressant use (p < 0.001). Bipolar disorder real-life management practice, irrespective of region, shows a delay in diagnosis and an overuse of antidepressants. Clinical decision-making appears to be based on a multidimensional approach related to current symptomatology and type of bipolar disorder. © 2016, Nature Publishing Group. All rights reserved.